($27.87) beat EPS estimates by 24 cents earning 83 cents a share premarket on Thursday, Nov. 7. The buy rated managed healthcare provider traded up to $31.02 then cracked below its 200-day SMA at $30.13 down to $25.40 on their missed revenue. Healthnet is 16.1% overvalued after gaining 10.9% over the last 12 months. My weekly pivot is $28.29 with annual risky levels at $32.54 and $35.35.
($4.89) beat EPS estimates by a penny reporting a loss of 28 cents in afterhours trading on Thursday, Nov. 7. The buy rated producer of rare earth oxides rebounded slightly off a multi-year low set at $4.61 on Nov.7 and Friday's high was $5.08. Molycorp is 28.6% overvalued after falling 31.8% over the last 12 months. My weekly and monthly risky levels are $5.40 and $5.88.
($55.80) missed EPS by 4 cents earning 53 cents a share in afterhours trading on Thursday, Nov.7. The buy rated distributor of energy drinks was downgraded to hold and has been trading around its 50-day and 200-day SMAs at $55.56 and $55.54 on Nov. 8 trading down to a day's low at $54.41.Monster is 12.7% overvalued after gaining 23.6% over the last 12 months. My weekly pivot is $55.50 with a semiannual risky level at $61.40.
($15.69) matched EPS estimates earning 20 cents a share in afterhours trading on Thursday, Nov. 7. The buy rated supplier of 3D graphics processors snapped higher from a Nov. 7 close at $14.55 trading as high as $15.73 on Monday and closing above its 50-day SMA at $15.43. Nvidia is 28.1% overvalued after gaining 31.7% over the last 12 months. My weekly value level is $15.23 with a quarterly pivot at $15.64 and monthly and semiannual risky levels at $16.28 and $17.21.
($1096.50) beat EPS estimates by $1.03 earning $16.67 a share in afterhours trading on Thursday, Nov. 7. When I profiled the stock I was questioning whether or not the company would sustain the grand a share price point. After briefly dipping below a grand in afterhours trading, the buy rated e-commerce pricing service company snapped back above it. The Nov. 7 close at $1022.89 was above the 50-day SMA at $1020.05 and Monday's new all-time high was $1109.50. Priceline is 28.4% overvalued after gaining 73.1% over the last 12 months. My quarterly value level at $1022.97 held at the low then my monthly pivot at $1077.01 became a magnet. This week's risky level is $1124.02.